Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Investig Med High Impact Case Rep ; 5(2): 2324709617703672, 2017.
Article in English | MEDLINE | ID: mdl-28491882

ABSTRACT

The hallmark manifestations of Cushing's syndrome (CS) are well known, but hypercoagulability is perhaps least recognized. Patients with CS are at increased risk of both spontaneous and postoperative thromboembolism, with the significant majority of events occurring in the lower extremity and pulmonary venous circulations. We present a case of portal vein thrombosis (PVT) occurring in the setting of newly diagnosed CS due to a left adrenal adenoma. Factor VIII activity was approximately 2.5-fold elevated, a known mechanism by which hypercortisolemia predisposes to venous thrombosis. Acute abdominal pain and fever responded well to unfractionated heparin and parenteral antibiotics, and CS was eventually cured by left adrenalectomy. No thromboembolic events have occurred since surgery. PVT is uncommon and usually occurs as a complication of primary or secondary hepatobiliary malignancies and cirrhosis. To the best of our knowledge, this is just the second reported case of PVT due to CS and the first published in the English language literature.

2.
Med Clin North Am ; 96(3): 635-54, xi, 2012 May.
Article in English | MEDLINE | ID: mdl-22703859

ABSTRACT

In Graves ophthalmopathy, immunotherapy is offering an opportunity of reducing bad outcomes that lead to disfigurement and impairment of vision. These therapies are not perfect; however, we now have a chance to achieve better outcomes. In asthma, immune therapy using passive immunity targeting key proinflammatory cytokine/chemokines and medications of their effects has opened an avenue of research into a safe and durable therapy. Omalizumab appears to be safe and effective in clinical use. In regional pain syndrome, immune mechanisms may be involved in sustaining long-standing pain, and IVIG may moderate pain sensitivity by reducing immune activation.


Subject(s)
Asthma/therapy , Complex Regional Pain Syndromes/therapy , Graves Ophthalmopathy/therapy , Immunotherapy/methods , Allergens/immunology , Anti-Asthmatic Agents/therapeutic use , Antibodies, Anti-Idiotypic/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Antibodies, Monoclonal, Murine-Derived/therapeutic use , Antioxidants/therapeutic use , Asthma/immunology , Asthma/physiopathology , Azathioprine/therapeutic use , Benzamides , Complex Regional Pain Syndromes/immunology , Cyclosporine/therapeutic use , Decompression, Surgical , Etanercept , Glucocorticoids/therapeutic use , Graves Ophthalmopathy/diagnosis , Graves Ophthalmopathy/immunology , Humans , Imatinib Mesylate , Immunoglobulin G/therapeutic use , Immunoglobulins, Intravenous/therapeutic use , Immunosuppressive Agents/therapeutic use , Octreotide/therapeutic use , Omalizumab , Orbit/radiation effects , Piperazines/therapeutic use , Pyridones/therapeutic use , Pyrimidines/therapeutic use , Radiotherapy Dosage , Receptors, Tumor Necrosis Factor/therapeutic use , Risk Factors , Rituximab , Selenium/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...